Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: A prospective study

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 12, 2015, Pages 1271-1280

  Cui, J ^a   Ang, B ^a   Haufe, W ^b   Hernandez, C ^a   Verna, E C ^c   Sirlin, C B ^b   Loomba, R ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE ALANINE AMINOTRANSFERASE RATIO; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; BODY MASS; BONACINI CIRRHOSIS DISCRIMINANT SCORE; CHEMICAL PARAMETERS; CLINICAL PREDICTION RULE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM DISEASE ASSESSMENT; ELASTOGRAPHY; FEMALE; FIB-4; GOLD STANDARD; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; LOK INDEX; MAGNETIC RESONANCE ELASTOGRAPHY; MAJOR CLINICAL STUDY; MALE; NAFLD FIBROSIS SCORE; NASH CRN MODEL; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; AGED; AREA UNDER THE CURVE; BIOPSY; COMPLICATION; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; AGED; AREA UNDER CURVE; BIOMARKERS; BIOPSY; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; ROC CURVE;

EID: 84929289615     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13196     Document Type: Article

References (49)

1. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
2. Loomba R, Sanyal AJ,. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-90.
3. Williams CD, Stengel J, Asike MI, et al,. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
4. Targher G, Day CP, Bonora E,. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50.
5. Loomba R, Abraham M, Unalp A, et al,. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943-51.
6. Williamson RM, Price JF, Glancy S, et al,. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 2011; 34: 1139-44.
7. Browning JD, Szczepaniak LS, Dobbins R, et al,. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
8. Arulanandan A, Ang B, Bettencourt R, et al,. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2015; doi: 10.1016/j.cgh.2015.01.027 [Epub ahead of print].
9. Zarrinpar A, Loomba R,. Systemic review: the emerging interplay between bile acids, gastrointestinal tract, and incretins in the pathogenesis of diabetes and nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 36: 909-21.
10. Angulo P, Keach JC, Batts KP, et al,. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
11. Adams LA, Lymp JF, St Sauver J, et al,. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
12. Udell JA, Wang CS, Tinmouth J, et al,. Does this patient with liver disease have cirrhosis? JAMA 2012; 307: 832-42.
13. Ekstedt M, Franzen LE, Mathiesen UL, et al,. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
14. Guzman G, Brunt EM, Petrovic LM, et al,. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008; 132: 1761-6.
15. Matteoni CA, Younossi ZM, Gramlich T, et al,. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
16. Ratziu V, Charlotte F, Heurtier A, et al,. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.
17. Angulo P, Hui JM, Marchesini G, et al,. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
18. Harrison SA, Oliver D, Arnold HL, et al,. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced fibrosis. Gut 2008; 57: 1441-7.
19. Williams AL, Hoofnagle JH,. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1998; 95: 734-9.
20. Sterling RK, Lissen E, Clumeck N, et al,. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
21. Wai C, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 28: 518-26.
22. Shah AG, Lydecker A, Murray K, et al,. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-12.
23. McPherson S, Stewart SF, Henderson E, et al,. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-9.
24. Adams LA, George J, Bugianesi E, et al,. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26: 1536-43.
25. Festi D, Schiumerini L, Marzi A, et al,. Review article: the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013; 37: 392-400.
26. Loomba R, Wolfson T, Ang B, et al,. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014; 60: 1920-8.
27. Kim D, Kim WR, Talwalkar JA, et al,. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 2013; 268: 411-9.
28. Bonacini M, Hadi G, Govindarajan S, et al,. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92: 1302-4.
29. Lok ASF, Ghany MG, Goodman ZD, et al,. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 42: 282-92.
30. Neuschwander-Tetri BA, Clark JM, Bass NM, et al,. Clinical, laboratory, and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913-24.
31. Le TA, Chen J, Changchien C, et al,. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012; 56: 922-32.
32. Loomba R, Sirlin CB, Ang B, et al,. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel MRI and MRE in a randomized trial (MOZART Trial). Hepatology 2015; 61: 1239-50.
33. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al,. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicenter, randomized, placebo-controlled trial. Lancet 2015; 385: 956-65.
34. Patel NS, Peterson MR, Brenner DA, et al,. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 37: 630-9.
35. Lin SC, Heba E, Wolfson T, et al,. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. Clin Gastroenterol Hepatol 2015; doi: 10.1016/j.cgh.2014.11.027 [Epub ahead of print].
36. Kleiner DE, Brunt EM, van Natta M, et al,. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
37. Matthews DR, Hosker JP, Rudenski AS, et al,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
38. Alberti KG, Zimmet P, Shaw J,. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
39. Yin M, Talwalkar JA, Glaser KJ, et al,. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5: 1207-13, e2.
40. Chen J, Talwalkar JA, Yin M, et al,. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259: 749-56.
41. Venkatesh SK, Yin M, Ehman RL,. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging 2013; 37: 544-55.
42. Permutt Z, Le TA, Peterson MR, et al,. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease-MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012; 36: 22-9.
43. Noureddin M, Lam J, Peterson MR, et al,. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013; 58: 1930-40.
44. Xavier R, Turck N, Hainard A, et al,. pROC: an open-source package for R and S+ to analyze and compare ROC curves". BMC Bioinformatics 2011; 12: 77.
45. Sing T, Sander O, Beerenwinkel N, et al,. ROCR: visualizing classifier performance in R. Bioinformatics 2005; 21: 7881.
46. DeLong ER, DeLong EM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
47. Vodkin I, Valasek MA, Bettencourt R, et al,. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther 2015; 41: 368-78.
48. Venkatesh SK, Yin M, Ehman RL,. Magnetic resonance elastography of the liver: clinical applications. J Comput Assist Tomogr 2013; 37: 887-96.
49. Loomba R, Cui J, Wolfson T, et al,. 3D magnetic resonance elastography is superior to 2D magnetic resonance elastography for advanced fibrosis diagnosis in patients with NAFLD. Poster presentation at AASLD 2014.